top of page

RS Oncology Announces Completion of First-in-Human Phase 1 Clinical Trial of RSO-021, a Novel Irreve

Cambridge, Mass., Sept 12, 2023 – RS Oncology, a clinical stage biotechnology company developing innovative therapies to eradicate mesothelioma and other diseases, today announced the completion of the Phase 1 dose escalation portion of the MITOPE study (NCT05278975).

The United Kingdom-based multicenter study met its primary objective of evaluating the safety and tolerability of RSO-021, a novel irreversible inhibitor of mitochondrial PRX3, in patients with malignant pleural mesothelioma and local disease affecting the lining of the lungs. These patients also had fluid on their lungs due to the cancer, which had failed to respond to at least one prior treatment.

"Concluding Phase 1 is a significant accomplishment towards bringing a potential new therapy to patients suffering from mesothelioma and other cancers of the lung,” said Jarrett Duncan, CEO of RS Oncology. “We thank the patients, caregivers, support groups and the clinical hospital teams who are participating and supporting our program around the UK.” “We look forward to sharing the full results of Phase 1 at a major cancer conference in 2024, as we continue our progress towards bringing this exciting new treatment to more patients,” added George Naumov, COO of RS Oncology.

For additional information about the trial, please visit using the identifier #NCT05278975.

About RS Oncology

RS Oncology (RSO) is a clinical stage biotechnology company based in Cambridge, Massachusetts with a mission to eradicate mesothelioma and other diseases worldwide through novel science and an innovative business model. The lead program is currently focused on development of novel therapies that modulate mitochondrial pathways driving diseases of oxidative stress, including mesothelioma and other cancers.

Corporate Inquiries: Jarrett Duncan, CEO

Media Inquiries: Christine Sununu, Marketing & Communications c.sununu@rsoncology.comComplete results anticipated to be shared in early 2024


bottom of page